{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T04:03:50Z","timestamp":1788926630941,"version":"build-2803163510"},"reference-count":27,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2024,9,28]],"date-time":"2024-09-28T00:00:00Z","timestamp":1727481600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"name":"NIH grants","award":["R01 CA262311"],"award-info":[{"award-number":["R01 CA262311"]}]},{"name":"NIH grants","award":["P50 CA097257"],"award-info":[{"award-number":["P50 CA097257"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,2,10]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Despite reassuring clinical and histological features, low-grade meningiomas can recur after surgery. Targeted gene expression profiling improves risk stratification of meningiomas, but the utility of this approach for clinical low-risk meningiomas is incompletely understood.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>This was a multicenter retrospective cohort study of meningiomas from patients who were treated at 4 institutions from 1992 to 2023. Adult patients with newly diagnosed or recurrent World Health Organization (WHO) grade 1 meningiomas that were treated with gross total resection (GTR) or subtotal resection (STR), or newly diagnosed WHO grade 2 meningiomas that were treated with GTR, were included. A 34-gene expression biomarker and gene expression risk score (continuous from 0 to 1) was evaluated in all samples.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>The study cohort was comprised of 723 patients, none of which were used for discovery or training of the gene expression biomarker and 265 of which were previously unreported. There were 626 WHO grade 1 meningiomas, 490 with GTR and 126 with STR, and 97 WHO grade 2 meningiomas with GTR. Targeted gene expression profiling classified 51.3% of clinical low-risk meningiomas as molecular intermediate-risk and 9.5% as molecular high-risk. Combining the gene expression biomarker with the extent of resection revealed that 19.8% of clinical low-risk meningiomas had unfavorable local freedom from recurrence (LFFR) and overall survival (OS), including 7.1% of newly diagnosed WHO grade 1 meningiomas with GTR. The risk score was prognostic for LFFR (HR per 0.1 increase in risk score 1.89, 95% CI: 1.58\u20132.25) across all WHO grades, extents of resection, and newly diagnosed or recurrent presentations.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Targeted gene expression profiling can identify clinical low-risk meningiomas that are likely to recur after surgery.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/neuonc\/noae198","type":"journal-article","created":{"date-parts":[[2024,9,28]],"date-time":"2024-09-28T12:10:28Z","timestamp":1727525428000},"page":"445-454","source":"Crossref","is-referenced-by-count":14,"title":["A targeted gene expression biomarker predicts clinic low-risk meningioma recurrence"],"prefix":"10.1093","volume":"27","author":[{"given":"Minh P","family":"Nguyen","sequence":"first","affiliation":[{"name":"Department of Pathology, University of California San Francisco , San Francisco, California ,","place":["USA"]},{"name":"Department of Neurological Surgery, University of California San Francisco , San Francisco, California ,","place":["USA"]},{"name":"Department of Radiation Oncology, University of California, San Francisco , San Francisco, California ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ramin A","family":"Morshed","sequence":"additional","affiliation":[{"name":"Department of Neurological Surgery, University of California San Francisco , San Francisco, California ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark W","family":"Youngblood","sequence":"additional","affiliation":[{"name":"Department of Neurological Surgery, Northwestern University , Chicago, Illinois ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haley K","family":"Perlow","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Ohio State University , Columbus, Ohio ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Calixto-Hope G","family":"Lucas","sequence":"additional","affiliation":[{"name":"Department of Oncology, Johns Hopkins University , Baltimore, Maryland ,","place":["USA"]},{"name":"Department of Neurosurgery, Johns Hopkins University , Baltimore, Maryland ,","place":["USA"]},{"name":"Department of Pathology, Johns Hopkins University , Baltimore, Maryland ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akash J","family":"Patel","sequence":"additional","affiliation":[{"name":"Jan and Dan Duncan Neurological Research Institute, Texas Children\u2019s Hospital , Houston, Texas ,","place":["USA"]},{"name":"Department of Neurosurgery, Baylor College of Medicine , Houston, Texas ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3311-0129","authenticated-orcid":false,"given":"Joshua D","family":"Palmer","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Ohio State University , Columbus, Ohio ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Craig M","family":"Horbinski","sequence":"additional","affiliation":[{"name":"Department of Neurological Surgery, Northwestern University , Chicago, Illinois ,","place":["USA"]},{"name":"Department of Pathology, Northwestern University , Chicago, Illinois ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen T","family":"Magill","sequence":"additional","affiliation":[{"name":"Department of Neurological Surgery, Northwestern University , Chicago, Illinois ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William C","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, University of California, San Francisco , San Francisco, California ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9299-8864","authenticated-orcid":false,"given":"David R","family":"Raleigh","sequence":"additional","affiliation":[{"name":"Department of Pathology, University of California San Francisco , San Francisco, California ,","place":["USA"]},{"name":"Department of Neurological Surgery, University of California San Francisco , San Francisco, California ,","place":["USA"]},{"name":"Department of Radiation Oncology, University of California, San Francisco , San Francisco, California ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,9,28]]},"reference":[{"issue":"12 Suppl 2","key":"2025021113125828200_CIT0001","doi-asserted-by":"crossref","first-page":"iv1","DOI":"10.1093\/neuonc\/noad149","article-title":"CBTRUS statistical report: Primary brain and other central nervous system tumors diagnosed in the United States in 2016-2020","volume":"25","author":"Ostrom","year":"2023","journal-title":"Neuro Oncol."},{"issue":"14","key":"2025021113125828200_CIT0002","doi-asserted-by":"crossref","first-page":"6458","DOI":"10.1002\/cam4.2516","article-title":"Trends in intracranial meningioma incidence in the United States, 2004-2015","volume":"8","author":"Lin","year":"2019","journal-title":"Cancer Med"},{"issue":"11","key":"2025021113125828200_CIT0003","doi-asserted-by":"crossref","first-page":"1821","DOI":"10.1093\/neuonc\/noab150","article-title":"EANO guideline on the diagnosis and management of meningiomas","volume":"23","author":"Goldbrunner","year":"2021","journal-title":"Neuro Oncol"},{"issue":"1","key":"2025021113125828200_CIT0004","doi-asserted-by":"crossref","first-page":"12","DOI":"10.6004\/jnccn.2023.0002","article-title":"NCCN Guidelines\u00ae insights: Central nervous system cancers, Version 2.2022","volume":"21","author":"Horbinski","year":"2023","journal-title":"J Natl Compr Canc Netw."},{"issue":"1","key":"2025021113125828200_CIT0005","doi-asserted-by":"crossref","first-page":"86","DOI":"10.3171\/2022.4.JNS212516","article-title":"Supervised machine learning algorithms demonstrate proliferation index correlates with long-term recurrence after complete resection of WHO grade I meningioma","volume":"138","author":"Nguyen","year":"2023","journal-title":"J Neurosurg."},{"issue":"2","key":"2025021113125828200_CIT0006","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1007\/s11060-018-2813-9","article-title":"Salvage therapy outcomes for atypical meningioma","volume":"138","author":"Chen","year":"2018","journal-title":"J Neurooncol."},{"issue":"6","key":"2025021113125828200_CIT0007","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1038\/s41588-024-01747-1","article-title":"Spatial genomic, biochemical and cellular mechanisms underlying meningioma heterogeneity and evolution","volume":"56","author":"Lucas","year":"2024","journal-title":"Nat Genet."},{"issue":"8","key":"2025021113125828200_CIT0008","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1093\/neuonc\/noab106","article-title":"The 2021 WHO classification of tumors of the central nervous system: A summary","volume":"23","author":"Louis","year":"2021","journal-title":"Neuro Oncol"},{"issue":"1","key":"2025021113125828200_CIT0009","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s11060-018-03067-x","article-title":"The prognostic significance of TERT promoter mutations in meningioma: a systematic review and meta-analysis","volume":"142","author":"Lu","year":"2019","journal-title":"J Neurooncol."},{"issue":"3","key":"2025021113125828200_CIT0010","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1007\/s00401-020-02188-w","article-title":"CDKN2A\/B homozygous deletion is associated with early recurrence in meningiomas","volume":"140","author":"Sievers","year":"2020","journal-title":"Acta Neuropathol."},{"issue":"3067","key":"2025021113125828200_CIT0011","first-page":"3076","article-title":"Targeted gene expression profiling predicts meningioma outcomes and radiotherapy responses","volume":"29","author":"Chen","year":"2023","journal-title":"Nat Med."},{"issue":"12","key":"2025021113125828200_CIT0012","doi-asserted-by":"crossref","first-page":"3020","DOI":"10.1038\/s41591-023-02642-8","article-title":"Meningioma risk stratification with a targeted gene-expression biomarker","volume":"29","author":"Chen","year":"2023","journal-title":"Nat Med."},{"issue":"2","key":"2025021113125828200_CIT0013","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1093\/neuonc\/noad212","article-title":"A 34-gene expression biomarker predicts meningioma outcomes and radiotherapy responses","volume":"26","author":"Raleigh","year":"2024","journal-title":"Neuro Oncol"},{"issue":"5","key":"2025021113125828200_CIT0014","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1093\/neuonc\/noab213","article-title":"A molecularly integrated grade for meningioma","volume":"24","author":"Driver","year":"2022","journal-title":"Neuro Oncol"},{"issue":"6","key":"2025021113125828200_CIT0015","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1007\/s00401-016-1545-1","article-title":"The 2016 World Health Organization Classification of Tumors of the Central Nervous System: A summary","volume":"131","author":"Louis","year":"2016","journal-title":"Acta Neuropathol."},{"issue":"5","key":"2025021113125828200_CIT0016","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1016\/S1470-2045(17)30155-9","article-title":"DNA methylation-based classification and grading system for meningioma: A multicentre, retrospective analysis","volume":"18","author":"Sahm","year":"2017","journal-title":"Lancet Oncol."},{"issue":"5","key":"2025021113125828200_CIT0017","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1038\/s41588-022-01061-8","article-title":"Meningioma DNA methylation groups identify biological drivers and therapeutic vulnerabilities","volume":"54","author":"Choudhury","year":"2022","journal-title":"Nat Genet."},{"issue":"8","key":"2025021113125828200_CIT0018","doi-asserted-by":"crossref","first-page":"2216","DOI":"10.1158\/1078-0432.CCR-20-3362","article-title":"Improved detection of postoperative residual meningioma with [68Ga]Ga-DOTA-TOC PET imaging using a high-resolution research tomograph PET scanner","volume":"27","author":"Bashir","year":"2021","journal-title":"Clin Cancer Res."},{"issue":"34","key":"2025021113125828200_CIT0019","doi-asserted-by":"crossref","first-page":"3839","DOI":"10.1200\/JCO.21.00784","article-title":"Integrated molecular-morphologic meningioma classification: A multicenter retrospective analysis, retrospectively and prospectively validated","volume":"39","author":"Maas","year":"2021","journal-title":"J Clin Oncol"},{"issue":"3","key":"2025021113125828200_CIT0020","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1093\/neuonc\/noac224","article-title":"Hypermitotic meningiomas harbor DNA methylation subgroups with distinct biological and clinical features","volume":"25","author":"Choudhury","year":"2023","journal-title":"Neuro Oncol."},{"issue":"5","key":"2025021113125828200_CIT0021","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.3171\/2019.8.JNS191266","article-title":"Correlations between genomic subgroup and clinical features in a cohort of more than 3000 meningiomas","volume":"133","author":"Youngblood","year":"2019","journal-title":"J Neurosurg."},{"key":"2025021113125828200_CIT0022","article-title":"Spatial distribution of meningiomas: A magnetic resonance image atlas [published online ahead of print August 28, 2024]","author":"Patel","journal-title":"Neurosurgery"},{"issue":"2","key":"2025021113125828200_CIT0023","doi-asserted-by":"crossref","first-page":"488","DOI":"10.3171\/2020.6.JNS201904","article-title":"The Simpson grade: Abandon the scale but preserve the message","volume":"135","author":"Schwartz","year":"2020","journal-title":"J Neurosurg."},{"issue":"7874","key":"2025021113125828200_CIT0024","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1038\/s41586-021-03850-3","article-title":"A clinically applicable integrative molecular classification of meningiomas","volume":"597","author":"Nassiri","year":"2021","journal-title":"Nature."},{"issue":"1","key":"2025021113125828200_CIT0025","doi-asserted-by":"crossref","first-page":"4803","DOI":"10.1038\/s41467-020-18582-7","article-title":"Multiplatform genomic profiling and magnetic resonance imaging identify mechanisms underlying intratumor heterogeneity in meningioma","volume":"11","author":"Magill","year":"2020","journal-title":"Nat Commun."},{"issue":"4","key":"2025021113125828200_CIT0026","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1093\/neuonc\/nov247","article-title":"Pathology concordance levels for meningioma classification and grading in NRG Oncology RTOG Trial 0539","volume":"18","author":"Rogers","year":"2016","journal-title":"Neuro Oncol"},{"key":"2025021113125828200_CIT0027","author":"Office of the State Actuary"}],"container-title":["Neuro-Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/neuro-oncology\/advance-article-pdf\/doi\/10.1093\/neuonc\/noae198\/60065179\/noae198.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/neuro-oncology\/article-pdf\/27\/2\/445\/60065179\/noae198.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/neuro-oncology\/article-pdf\/27\/2\/445\/60065179\/noae198.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,11]],"date-time":"2025-02-11T13:13:21Z","timestamp":1739279601000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/neuro-oncology\/article\/27\/2\/445\/7787198"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,28]]},"references-count":27,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2024,9,28]]},"published-print":{"date-parts":[[2025,2,10]]}},"URL":"https:\/\/doi.org\/10.1093\/neuonc\/noae198","relation":{},"ISSN":["1522-8517","1523-5866"],"issn-type":[{"value":"1522-8517","type":"print"},{"value":"1523-5866","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,2]]},"published":{"date-parts":[[2024,9,28]]}}}